Evidence map›Paper›PMID 37261501›Full record

ArticleJournal of neurology2023

Progression of initially unilateral Moyamoya angiopathy in Caucasian Europeans.

Daniel Strunk, Rolf R Diehl, Roland Veltkamp, Sven G Meuth, Markus Kraemer

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Research progress in unilateral moyamoya disease.Frontiers in human neuroscience · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Daniel StrunkDepartment of Neurology, European Reference Center for Moyamoya Angiopathy (VASCERN, ERN), Alfried Krupp Hospital, Alfried-Krupp-Straße 21, 45131, Essen, Germany.
Rolf R DiehlDepartment of Neurology, European Reference Center for Moyamoya Angiopathy (VASCERN, ERN), Alfried Krupp Hospital, Alfried-Krupp-Straße 21, 45131, Essen, Germany.
Roland VeltkampDepartment of Neurology, European Reference Center for Moyamoya Angiopathy (VASCERN, ERN), Alfried Krupp Hospital, Alfried-Krupp-Straße 21, 45131, Essen, Germany.
Sven G MeuthDepartment of Neurology, Medical Faculty, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany.
Markus KraemerDepartment of Neurology, European Reference Center for Moyamoya Angiopathy (VASCERN, ERN), Alfried Krupp Hospital, Alfried-Krupp-Straße 21, 45131, Essen, Germany. markus.kraemer@krupp-krankenhaus.de.ORCID http://orcid.org/0000-0002-5667-3621
Alfried Krupp Hospital · DEHeinrich Heine University Düsseldorf · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMoyamoya angiopathy (MMA) is a rare cause of stroke in Caucasians, but it is much more frequent in East Asia. Since 2021, diagnostic criteria not only comprise bilateral, but also unilateral MMA. Hitherto, progression of unilateral MMA has predominantly been described in East Asians. Our study aimed to analyze the occurrence and characteristics of progression of initially unilateral MMA in Caucasian Europeans.

methodsBy retrospective analysis of medical records of 200 European Caucasians with MMA, admitted to our German center between 2010 and 2022, cases of unilateral MMA and its progression, i.e. progressive ipsi- or novel contralateral arterial stenosis, during follow-up were identified. Kruskal Wallis Test and Fisher's Exact Test were used to identify statistically significant differences between progressive and stable patients concerning demographic, clinical, laboratory, and radiographic features.

resultsOur cohort comprised 63 patients with initially unilateral MMA. Fourteen (22.2%) had an ipsi- (n = 3, 21.4%) or contralateral (n = 11, 78.6%) progression. Mean age of patients with progressive MMA at symptom onset was 32 ± 14.1 years. The ratio of women to men in this subgroup was 2.5:1. Mean follow-up period was 5.4 ± 3.7 years, mean age at progression was 39.9 ± 12.7 years. Mean time interval between penultimate follow-up and progression was 4.8 ± 4.5 years. Patients with progression showed affection of the posterior cerebral artery (p = 0.009) and suffered from vertigo (p = 0.009) significantly more often.

conclusionUnilateral MMA progresses in a substantial proportion in European Caucasians. Long-term follow-up is required due to potential late progression with consecutive symptoms and the need for bypass surgery.

Indexed as

Moyamoya DiseaseStrokeAdolescentAdultEuropean PeopleFemaleHumansMaleMiddle AgedRetrospective StudiesWhite PeopleYoung AdultBypassEuropean CaucasiansMoyamoya angiopathyProgressionUnilateral

Identifiers

PMID37261501
OpenAlexW4378953380

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.